Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.10% | -9.99% | 49.10% | -3.77% | -6.09% |
| Total Depreciation and Amortization | -43.74% | -16.85% | 426.73% | -27.91% | -8.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 140.11% | -55.04% | -91.40% | 82.43% | 65.08% |
| Change in Net Operating Assets | 171.73% | 4.57% | 142.89% | 26.73% | -114.35% |
| Cash from Operations | -5.46% | -15.38% | 45.95% | 9.46% | -474.09% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.19% | 3.46% | -39.00% | 143,600.00% | 382,500.00% |
| Cash from Investing | 39.19% | 3.46% | -39.00% | 143,487.50% | 382,500.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | 20.90% | -1,150.00% | 99.07% | -700.00% | -55.81% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15,016.42% | -- | 1,238.00% | -100.48% | -160.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 746.05% | -43.82% | -12.32% | 86.07% | 29.97% |